Trial Profile

HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Apr 2012 NCT reports actual end date as Oct 2011.
09 Jan 2012 Primary endpoint 'Symptom-exacerbation-rate' was met with vilanterol/fluticasone furoate 25/100µg, but not with the 25/200µg and 25/50µg doses, according to a GlaxoSmithKline and Theravance media release.
09 Jan 2012 Status changed from active, no longer recruiting to completed, according to a GlaxoSmithKline and Theravance media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com